Bruce A. Beutel

GRO Biosciences, Inc. develops genomically recoded organisms to express therapeutic proteins. The company was founded by George McDonald Church, Andrew D. Ellington, Daniel J. Mandell, Christopher J. Gregg, P. Benjamin Stranges, Marc J. Lajoie, and Ross Thyer in 2016 and is headquartered in Cambridge, MA.

Boston Immune Technologies & Therapeutics, Inc. is a company based in MA that develops a novel class of antagonist antibodies targeting the TNF superfamily receptors for applications in oncology, inflammation, autoimmunity, and infectious disease. The company is based in Winchester, MA. The company is also developing additional TNF superfamily antibodies including CD40 antagonists for inflammation and CD30 antagonists for oncology. The company was founded by Russell LaMontagne and he has been the CEO since incorporation.

Qiming US Ventures Management LLC (Qiming Venture Partners) is a venture capital subsidiary of Qiming Venture Partners Ltd founded in 2017 by Mark D. McDade and Gary Edward Rieschel. The firm is headquartered in Cambridge, Massachusetts.

Enveda Therapeutics, Inc. is a biotechnology company based in Boulder, CO. The company has developed a drug discovery search engine that utilizes metabolomics and machine learning to create a high-resolution chemical map of the natural world. Enveda's team includes experienced drug hunters and data scientists who work together to tackle the toughest problems in drug discovery. The company was founded by Viswa Colluru and Pieter Dorrestein, with Viswa Colluru serving as CEO since incorporation.

Znomics, Inc. is a shell company, which is seeking and investigating potential assets, property or businesses to acquire and intend to commence operations in the future through the acquisition of a going concern. It was previously an exploration stage company that was set up to engage in the exploration of mineral properties. Znomics was founded on March 20, 2006 and is headquartered in Minneapolis, MN.

PharmaGenics, Inc. develops therapeutic products for cancer. The American company was founded by Mike I. Sherman. PharmaGenics was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on June 18, 1997 for $112 million.